About Us
Type 2 Diabetes Mellitus (T2DM) is a chronic and progressive condition characterised by worsening glucose control over time. This process is driven by deterioration of the cells in the body that make insulin, the pancreatic beta cells. Current therapies for early type 2 diabetes can improve glucose control but they do not protect the pancreatic beta cells from deterioration.
PREVAIL is a government funded clinical trial for people with early T2DM. Our aim is to investigate therapies to protect the pancreatic beta cells and slow the progression of diabetes. We are currently inviting participants to join our study.
The trial is being conducted by Dr. Ravi Retnakaran at the Leadership Sinai Centre for Diabetes (LSCD) located at Mount Sinai Hospital. The LSCD is a leader in diabetes care through clinical practice, patient education and research and regularly conducts T2DM clinical trials.
